Safety of topotecan in the treatment of recurrent small-cell lung cancer and ovarian cancer (Q36689071)

15 August 2017

1 reference

title

Safety of topotecan in the treatment of recurrent small-cell lung cancer and ovarian cancer (English)

1 reference

15 August 2017

1 reference

Jennifer Garst

1

1 reference

PubMed ID

17181452

15 August 2017

language of work or name

English

0 references

publication date

1 January 2007

1 reference

Expert Opinion on Drug Safety

15 August 2017

1 reference

15 August 2017

6

1 reference

15 August 2017

1

1 reference

15 August 2017

53-62

1 reference

Hematologic safety and tolerability of topotecan in recurrent ovarian cancer and small cell lung cancer: an integrated analysis

15 August 2017

1 reference

https://api.crossref.org/works/10.1517%2F14740338.6.1.53

Topotecan, an active drug in the second-line treatment of epithelial ovarian cancer: results of a large European phase II study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.6.1.53

Topotecan in platinum- and paclitaxel-resistant ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.6.1.53

Topotecan dosing guidelines in ovarian cancer: reduction and management of hematologic toxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.6.1.53

Topotecan in the treatment of elderly patients with relapsed small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.6.1.53

Phase ii comparator study of oral versus intravenous topotecan in patients with chemosensitive small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.6.1.53

Topotecan in the treatment of relapsed small cell lung cancer patients with poor performance status

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.6.1.53

Update on the role of topotecan in the treatment of recurrent ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.6.1.53

Topotecan, pegylated liposomal doxorubicin hydrochloride and paclitaxel for second-line or subsequent treatment of advanced ovarian cancer: a systematic review and economic evaluation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.6.1.53

Improved therapeutic index of lower dose topotecan chemotherapy in recurrent ovarian cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.6.1.53

Weekly topotecan in the management of ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.6.1.53

Alternate dosing schedules for topotecan in the treatment of recurrent ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.6.1.53

A dose-escalating study of weekly bolus topotecan in previously treated ovarian cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.6.1.53

Phase II study of weekly topotecan in patients with recurrent or persistent epithelial ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.6.1.53

Open-label, multicenter, randomized, phase III study comparing oral topotecan/cisplatin versus etoposide/cisplatin as treatment for chemotherapy-naive patients with extensive-disease small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.6.1.53

Combination of topotecan and cisplatin in relapsed patients with small cell lung cancer: a phase II study of the hellenic cooperative oncology group (HeCOG).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.6.1.53

A weekly regimen of cisplatin, paclitaxel and topotecan with granulocyte-colony stimulating factor support for patients with extensive disease small cell lung cancer: a phase II study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.6.1.53

Activity and pharmacodynamics of 21-Day topotecan infusion in patients with ovarian cancer previously treated with platinum-based chemotherapy. New York Gynecologic Oncology Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.6.1.53

Topotecan given as a 21-day infusion in the treatment of advanced ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.6.1.53

A phase II and pharmacokinetic study of weekly 72-h topotecan infusion in patients with platinum-resistant and paclitaxel-resistant ovarian carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.6.1.53

A phase I study of dose-dense topotecan given upfront to standard therapy in patients with small cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.6.1.53

Efficacy of a toxicity-adjusted topotecan therapy in recurrent small cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.6.1.53

21 January 2018

Identifiers

DOI

10.1517/14740338.6.1.53

1 reference

15 August 2017

1 reference

PubMed ID

17181452